Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy
about
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A ReviewConstitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma.The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoeditingMechanisms of malignant glioma immune resistance and sources of immunosuppressionInduction of tumor inhibitory anti-angiogenic response through immunization with interferon Gamma primed placental endothelial cells: ValloVax™.IFNγ producing CD8(+) T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomasCellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionMultiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.Immunotherapy for melanoma: current status and perspectives.Epigenetic regulation of immune escape genes in cancer.Immune selective pressure and HLA class I antigen defects in malignant lesions.Molecular and genetic properties of tumors associated with local immune cytolytic activity.Immunotherapy for prostate cancer: biology and therapeutic approachesRegressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes."Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.Targeting HLA class I expression to increase tumor immunogenicity.Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.Newer developments in the immunotherapy of malignant melanoma.Bioinformatics for cancer immunotherapy target discovery.Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Immunotherapy eradicates metastases with reversible defects in MHC class I expression.Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B.Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.β2-microglobulin gene duplication in cetartiodactyla remains intact only in pigs and possibly confers selective advantage to the species.Deciphering the genetic evolution of T-cell resistance in melanoma.High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.Vaccination with beta(2)-microglobulin-deficient dendritic cells protects against growth of beta(2)-microglobulin-deficient tumours.Using single nucleotide variations in single-cell RNA-seq to identify subpopulations and genotype-phenotype linkage
P2860
Q54399872-0124A0B3-0AD4-4C4C-B712-864683EBF549Q54399991-FBB13BD5-B091-4BC6-A362-A59BCE1BB08EQ54581023-CDFC13FA-80F9-416D-B28C-48757590DAC1Q54581027-75B40534-7560-4DB1-85AD-CA873D5FA119Q54581206-70D3CB31-FDFB-40AF-9567-46EB30CDEF26Q54814108-E00BB078-5F87-48C5-8391-8A8849F84739Q54905083-2123A837-025B-4713-810E-B13C51257F07
P1343
Q28080338-1BEC6344-10A2-43A0-9E1A-80979766EF05Q33622596-D7B25E72-E954-4297-95FA-715219EECC34Q34208784-0E3F648A-3C3D-4CA0-9B8A-96BEB0E38F00Q34445188-9D9666A0-1EF8-4F92-8C5B-F15FD3D00CCAQ34661793-7846437E-4572-4885-B90D-481F20821FCCQ35187503-E3218C19-D648-4D1C-9874-E05D8B72F8F3Q35507485-4C8595C2-623A-4F8A-AC0A-5A412A85CE44Q35847139-C1B35112-03A1-43A3-BC8F-6A79436B7300Q36184954-CCF537D6-700C-41B2-B797-D704EC1717DCQ36283696-17FBC74E-24A3-43D6-8A45-6073E27AA4E1Q36453216-F3E36129-9991-45D4-8C6E-5053E893314BQ36471068-24B5C876-0289-4AE5-A25C-CAB2F584B8BDQ36510930-9FA6D4F8-B849-415E-B80B-86AB218CB2A1Q36869059-BF0E79E6-A1A0-4A51-BEB8-29E4D68DFC69Q36910465-5388704A-33A2-4FB1-BC5B-2FBC12AD4588Q37168266-B55B44B0-53D8-43EB-A306-4F0FBB7CDF8BQ37474753-1DAC5228-CB63-49A0-9AE4-6D307D173A43Q37697126-C51FC4E6-A4E9-423B-80C1-C7DE1EADF6C2Q37773238-BCB1B14F-15AF-4D90-AD39-2B81FDE4E271Q37804476-5ABE09B9-DDA2-4632-8F6B-F5954EE3641FQ37981721-65556290-09F6-45C5-BB56-64301D728B36Q38029543-5D095037-AEF7-4E72-B52E-D567A94F3A4FQ38049494-4D0AB95B-ECA4-4242-AD96-3A6AFC64FC0FQ38084132-32701453-BA6E-46DD-84BC-73AE32ADACCAQ38262688-CF71A456-C886-446C-8237-2BB57D4C94FFQ38282541-A41CA7A8-01FB-4B89-A118-1D4A495A2150Q38980455-0AC697F6-A16C-47D1-8B1B-496C898F2B28Q39137410-44303F96-B4D2-498F-9429-4C5E4C7BAEABQ39164068-283424BD-F6DE-4C24-9AF8-408AEBBA87BAQ39312652-D222DEF3-3797-4964-BC59-FD2E9291502AQ39546174-A7BD8E10-439D-4B23-B6AA-3006DFA47B32Q39904227-9FFA5AF0-1863-40A5-BCA4-C745FEB69BAEQ40088374-7ECED61D-C831-4957-B0F2-76B96AB50FF9Q40285760-1791D60F-F5A9-4364-AE77-4A5522A94A8EQ41433006-0FDD03E7-58C7-44B7-A45A-91A322C7A672Q41592557-453E5C63-A5B4-4F34-B62A-780C97C28F3FQ52737068-9F8693B3-1271-4569-AAC1-31A9E65F1B24Q53389702-B2B95875-C69E-4492-BE94-A9F41355F174Q59134696-94F9194B-FAF3-44C5-BA9C-C19BA567CE50
P2860
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Immune selection of hot-spot b ...... stases following immunotherapy
@ast
Immune selection of hot-spot b ...... stases following immunotherapy
@en
type
label
Immune selection of hot-spot b ...... stases following immunotherapy
@ast
Immune selection of hot-spot b ...... stases following immunotherapy
@en
prefLabel
Immune selection of hot-spot b ...... stases following immunotherapy
@ast
Immune selection of hot-spot b ...... stases following immunotherapy
@en
P2093
P2860
P4510
P1476
Immune selection of hot-spot b ...... stases following immunotherapy
@en
P2093
Chien-Chung Chang
Michael Campoli
Nicholas P Restifo
Soldano Ferrone
Xinhui Wang
P2860
P304
P356
10.4049/JIMMUNOL.174.3.1462
P407
P577
2005-02-01T00:00:00Z